The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | The current state of MRD-based therapy for myeloma
Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, talks on the use of measurable residual disease (MRD)-guided therapy for myeloma, discussing its prospects and challenges of its use. Dr Callander explains that patients who achieve sustained MRD-negativity demonstrate improved outcomes; however, it remains to be seen whether MRD-negativity can be sustained longer-term. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
